SH3BP2 antibody | knockout validation | Abnova H00006452-M01

This is a knockout-validated antibody summary, based on the publication "RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG2a, Kappa

Company: Abnova

Antibody: SH3BP2

Catalog number: H00006452-M01

Summary: Mouse monoclonal antibody raised against a partial recombinant SH3BP2 (452 a.a. ~ 561 a.a). Reacts with human by western blot, immunofluorescence and ELISA.

Validation Method

Western blot

Sample

Osteoclasts derived from WT, Rnf146fl/fl LysM-Cre, and Rnf146fl/fl Sh3bp2fl/fl LysM-Cre. Cells were lysed with RIPA buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 1% NP40, 0.1% SDS, 0.25% sodium deoxycholate, 1 mM EDTA) supplemented with protease and phosphatase inhibitors.

Blocking agent

5% BSA or 5% nonfat dried milk in PBST (PBS + 0.1% Tween-20).

Figure

Whole cell lysates from osteoclasts derived from WT, Rnf146fl/fl LysM-Cre (KO), and Rnf146fl/fl Sh3bp2fl/fl LysM-Cre (dKO) were probed with the indicated antibodies for western blot analysis. Please see Figure 5d in the article [1].

Clone note

The same clone (1E9) is sold as LifeSpan Biosciences LS-C198186; Abnova H00006452-M01; Sigma-Aldrich WH0006452M1.

References
  1. Matsumoto Y, LaRose J, Kent O, Lim M, Changoor A, Zhang L, et al. RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146.. J Clin Invest. 2017;127:1303-1315 pubmed publisher